Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors

<p>Abstract</p> <p>Background</p> <p>Oxaliplatin, an effective antineoplastic agent againstgastrointestinal tumors, can cause severe peripheral neurotoxicity, which seriously limits its clinical application. To date, there are no effective treatments for this complicati...

Full description

Bibliographic Details
Main Authors: Zhu Yanyun, Yang Junlan, Jiao Shunchang, Ji Tiefeng
Format: Article
Language:English
Published: BMC 2013-01-01
Series:World Journal of Surgical Oncology
Subjects:
Online Access:http://www.wjso.com/content/11/1/19
_version_ 1818364243443974144
author Zhu Yanyun
Yang Junlan
Jiao Shunchang
Ji Tiefeng
author_facet Zhu Yanyun
Yang Junlan
Jiao Shunchang
Ji Tiefeng
author_sort Zhu Yanyun
collection DOAJ
description <p>Abstract</p> <p>Background</p> <p>Oxaliplatin, an effective antineoplastic agent againstgastrointestinal tumors, can cause severe peripheral neurotoxicity, which seriously limits its clinical application. To date, there are no effective treatments for this complication. Ganglioside-monosialic acid (GM1) has been shown to protect neurons against injuries and degeneration. The aim of this study was to evaluate the effects of GM1 on preventing oxaliplatin-induced neurotoxicity in patients with gastrointestinal tumors.</p> <p>Methods</p> <p>In this study, 120 patients with gastrointestinal tumors were enrolled, andthey received the treatment of XELOX (oxaliplatin and capecitabine) and FOLFOX4 (oxaliplatin, leukovolin and 5-fluorouracil). The patients were randomly divided into two groups, the experimental group and control group, with60 patients ineach. On the day chemotherapy was initiated, the experimental group received GM1 intravenously (100 mg once daily) for 3 days, while no neuroprotective agents were applied in the control group. The incidence rates and classification of neurotoxicity in the two groups were evaluated and the differences between the two groups were examined. Furthermore, whether GM1 affected the therapeutic effects of chemotherapy was also examined.</p> <p>Results</p> <p>The grade of neurotoxicity in the experimental group was significantly lower than in the control group (<it>P</it><0.05, Mann–Whitney U test). The probability of occurrence of low-grade neurotoxicity (grade 0 and 1) in the experimental group was higher than that in the control group (logistic ordinal regression); whereas the probability of occurrence of high-grade neurotoxicity (grade 2 and 3) in the experimental group was lower than in the control group (logistic ordinal regression).</p> <p>Conclusion</p> <p>The data suggested that GM1 could reduce the grade of oxaliplatin-induced neurotoxicity and was an effective neuroprotective agent against oxaliplatin-induced high-grade neurotoxicity in patients with gastrointestinal tumors.</p>
first_indexed 2024-12-13T22:01:16Z
format Article
id doaj.art-c411300e015d4f4691b8b5f52df713e3
institution Directory Open Access Journal
issn 1477-7819
language English
last_indexed 2024-12-13T22:01:16Z
publishDate 2013-01-01
publisher BMC
record_format Article
series World Journal of Surgical Oncology
spelling doaj.art-c411300e015d4f4691b8b5f52df713e32022-12-21T23:30:00ZengBMCWorld Journal of Surgical Oncology1477-78192013-01-011111910.1186/1477-7819-11-19Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumorsZhu YanyunYang JunlanJiao ShunchangJi Tiefeng<p>Abstract</p> <p>Background</p> <p>Oxaliplatin, an effective antineoplastic agent againstgastrointestinal tumors, can cause severe peripheral neurotoxicity, which seriously limits its clinical application. To date, there are no effective treatments for this complication. Ganglioside-monosialic acid (GM1) has been shown to protect neurons against injuries and degeneration. The aim of this study was to evaluate the effects of GM1 on preventing oxaliplatin-induced neurotoxicity in patients with gastrointestinal tumors.</p> <p>Methods</p> <p>In this study, 120 patients with gastrointestinal tumors were enrolled, andthey received the treatment of XELOX (oxaliplatin and capecitabine) and FOLFOX4 (oxaliplatin, leukovolin and 5-fluorouracil). The patients were randomly divided into two groups, the experimental group and control group, with60 patients ineach. On the day chemotherapy was initiated, the experimental group received GM1 intravenously (100 mg once daily) for 3 days, while no neuroprotective agents were applied in the control group. The incidence rates and classification of neurotoxicity in the two groups were evaluated and the differences between the two groups were examined. Furthermore, whether GM1 affected the therapeutic effects of chemotherapy was also examined.</p> <p>Results</p> <p>The grade of neurotoxicity in the experimental group was significantly lower than in the control group (<it>P</it><0.05, Mann–Whitney U test). The probability of occurrence of low-grade neurotoxicity (grade 0 and 1) in the experimental group was higher than that in the control group (logistic ordinal regression); whereas the probability of occurrence of high-grade neurotoxicity (grade 2 and 3) in the experimental group was lower than in the control group (logistic ordinal regression).</p> <p>Conclusion</p> <p>The data suggested that GM1 could reduce the grade of oxaliplatin-induced neurotoxicity and was an effective neuroprotective agent against oxaliplatin-induced high-grade neurotoxicity in patients with gastrointestinal tumors.</p>http://www.wjso.com/content/11/1/19Gastrointestinal tumorsGanglioside-monosialic acidOxaliplatinNeurotoxicity
spellingShingle Zhu Yanyun
Yang Junlan
Jiao Shunchang
Ji Tiefeng
Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors
World Journal of Surgical Oncology
Gastrointestinal tumors
Ganglioside-monosialic acid
Oxaliplatin
Neurotoxicity
title Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors
title_full Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors
title_fullStr Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors
title_full_unstemmed Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors
title_short Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors
title_sort ganglioside monosialic acid gm1 prevents oxaliplatin induced peripheral neurotoxicity in patients with gastrointestinal tumors
topic Gastrointestinal tumors
Ganglioside-monosialic acid
Oxaliplatin
Neurotoxicity
url http://www.wjso.com/content/11/1/19
work_keys_str_mv AT zhuyanyun gangliosidemonosialicacidgm1preventsoxaliplatininducedperipheralneurotoxicityinpatientswithgastrointestinaltumors
AT yangjunlan gangliosidemonosialicacidgm1preventsoxaliplatininducedperipheralneurotoxicityinpatientswithgastrointestinaltumors
AT jiaoshunchang gangliosidemonosialicacidgm1preventsoxaliplatininducedperipheralneurotoxicityinpatientswithgastrointestinaltumors
AT jitiefeng gangliosidemonosialicacidgm1preventsoxaliplatininducedperipheralneurotoxicityinpatientswithgastrointestinaltumors